01—Abstract
Summary
Summary of the 10-Q filed November 4, 2026. Cited figures are marked; the original filing is the authoritative source.
Merck & Co., Inc. reported mixed financial results for the nine months ended September 30, 2026.
While total sales increased by 5% year-over-year to $50.98 billiona, driven by growth in oncology and animal health segments, the company incurred a significant net loss of $510 million attributable to Merck & Co., Inc. This loss is largely due to substantial research and development expenses associated with major acquisitions, including Cidara Therapeutics ($9.0 billion charge) and Terns Pharmaceuticals ($5.7 billion charge), impacting the bottom line for the period. Despite the net loss, operational cash flow remained strong at $15.8 billion. The company also continues to manage market access and pricing pressures globally, with specific impacts from the Inflation Reduction Act on key products like Januvia and Janumet.
The balance sheet shows a decrease in cash and cash equivalents to $9.55 billionb from $14.57 billion at the end of 2025, alongside an increase in long-term debt to $49.69 billion. This reflects the significant investment in business development activities during the period.
Merck continues to invest heavily in its pipeline, evidenced by the substantial R&D expenses and the strategic acquisitions aimed at bolstering its oncology and infectious disease portfolios. Investors should monitor the successful integration of these acquisitions and the performance of Keytruda and other key products amidst ongoing pricing and regulatory challenges.
02—Key points
Key Highlights
- Total sales increased by 5% to $50.98 billion for the nine months ended September 30, 2026, compared to the prior year period.
- Merck reported a net loss of $510 million for the nine months ended September 30, 2026, a significant shift from a net income of $15.3 billion in the same period of 2025, primarily due to acquisition-related R&D charges.
- Significant business development activity in 2026 included major acquisitions of Cidara Therapeutics ($9.2 billion) and Terns Pharmaceuticals ($6.8 billion), resulting in substantial R&D expense charges.
- Operating cash flow remained strong, at $15.8 billion for the nine months ended September 30, 2026.
- The Pharmaceutical segment saw sales growth, driven by Keytruda/Keytruda Qlex and Welireg, while the Animal Health segment also contributed positively to revenue.
- Keytruda/Keytruda Qlex sales increased 7% year-over-year to $25.0 billion for the first nine months of 2026, demonstrating continued strong performance.
- The company's cash and cash equivalents decreased to $9.55 billion as of September 30, 2026, from $14.57 billion at December 31, 2025, while long-term debt increased to $49.69 billion.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-QQ3 FY2026filed November 4, 2026Financial Statements
Q3 FY2026 against Q3 FY2025
| Line item | Q3 FY2026Q3 FY2025 | Change |
|---|---|---|
| Revenue | $18.09B$17.28B | +4.7% |
| Cost of Revenue | $4.89B$3.85B | +26.9% |
| Gross Profit | $13.19B$13.42B | −1.7% |
| R&D Expenses | $4.54B$4.23B | +7.2% |
| SG&A Expenses | $2.89B$2.63B | +9.6% |
| Net Income | $5.07B$5.79B | −12.4% |
| EPS (Basic) | $2.05$2.32 | −11.6% |
| EPS (Diluted) | $2.04$2.32 | −12.1% |
| Shares Outstanding (Basic) | 2.47B2.50B | −1.1% |
| Shares Outstanding (Diluted) | 2.48B2.50B | −0.8% |
05—Questions
Frequently Asked Questions
What drove the significant net loss in the first nine months of 2026 despite increased sales?
The net loss of $510 million for the nine months ended September 30, 2026, despite a 5% increase in sales, was primarily driven by substantial research and development expenses related to significant business development transactions. Specifically, the acquisitions of Cidara Therapeutics and Terns Pharmaceuticals incurred charges of $9.0 billion and $5.7 billion, respectively, for acquired in-process research and development (IPR&D) with no alternative future use, which were recorded as R&D expenses.
How is Merck managing pricing pressures and regulatory changes, such as those from the Inflation Reduction Act (IRA)?
Merck is facing ongoing pricing pressures globally. The Inflation Reduction Act (IRA) has led to government price setting for key products like Januvia, Janumet, and Janumet XR, effective in 2026 and 2027. Additionally, the company is navigating changes in the Medicare Part D program and potential impacts from international pricing benchmarks. Merck has entered into various agreements, including a three-year Most-Favored-Nation (MFN) Agreement with the U.S. government, to address some of these pricing concerns and ensure access to its medicines.
What is the outlook for Keytruda and Keytruda Qlex sales?
Keytruda and Keytruda Qlex continue to be strong performers, with combined global sales growing 7% year-over-year to $25.0 billion for the first nine months of 2026. Growth in the U.S. is driven by higher net pricing and increased utilization across earlier-stage indications. International market growth is attributed to uptake in earlier-stage indications and higher demand in metastatic indications. Despite some market access challenges and the anticipation of biosimilar erosion in smaller markets, the outlook remains positive, supported by numerous regulatory approvals in 2026 across various cancer types and geographies.
How has Merck's debt and cash position changed, and what is the impact of recent acquisitions?
Merck's financial position shows a decrease in cash and cash equivalents to $9.55 billion as of September 30, 2026, down from $14.57 billion at the end of 2025, reflecting significant cash outflows for acquisitions and share repurchases. Concurrently, long-term debt increased to $49.69 billion from $46.75 billion. This shift is primarily due to funding large acquisitions like Cidara and Terns, and the issuance of $6.0 billion in senior unsecured notes. Despite increased leverage, operational cash flow remains robust, providing liquidity for ongoing operations and strategic initiatives.
06—Continue